HEPATITIS-B virus reactivation
has occurred in patients who are
chronic carriers of the virus after
they received Bcr-Abl tyrosine
kinase inhibitors, used to treat their
chronic myeloid leukaemia, the
Therapeutic Goods Administration
has warned in its latest Medicines
Safety Update.
Other alerts relate to the use of
bone density enhancer denosumab
(Xgeva or Prolia) use associated
with QT prolongation as well as
psychiatric adverse events that
have occured in patients treated
with cystic acne treatment
isotretinoin, marketed in Australia
as Roaccutane and multiple
generics.
Visit www.tga.gov.au for details.The above article was sent to subscribers in Pharmacy Daily's issue from 12 Aug 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 12 Aug 16
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.